NCP Flanders
choose your programme
Horizon Europe

Horizon Europe is the main Research and Innovation Funding Programme of the European Commission.

Horizon 2020

Horizon 2020 is the previous Funding Programme. There are no longer calls, but projects can run until 2024.

Digital Europe

Digital Europe is a Funding Programme focused on bringing digital technology to businesses, citizens and administrations.

Other EU Funding

There are many other relevant EU funding programmes, managed by several agencies and directorates.

News and Updates

Find out what's happening in the area of Horizon Europe, Digital Europe and Horizon 2020

Updated call document: Advanced Digital Skills (DIGITAL-2024-ADVANCED-DIGITAL-07)

Published on | 4 months ago

Programmes Advanced Digital Skills  

Please not that the call document for call Advanced Digital Skills (DIGITAL-2024-ADVANCED-DIGITAL-07) has been updated.

The following paragraph - section 2, page 8, last paragraph on the page - of the Call document is updated as below. 

Each participating higher education institution (minimum 3; see section Targeted stakeholders) needs to offer and deliver the programme at ISCED levels 6 (Bachelor's or equivalent level) or 7 (Master's or equivalent level) to a minimum of 25 students per programme cycle. In this respect, delivering a joint master is not a requirement of this call topic. At least one full cycle of the programme should be delivered and at least one second cycle of the programme should start during the duration of the project (48 months). This results in a minimum of at least 150 students enrolled in the programme(s) during the duration of the project (min. 3 institutions, min. 25 students per programme cycle, min. 2 cycles). Participating higher education institutions that intend to design and deliver programme(s) exclusively at ISCED level 8 (doctoral or equivalent level) must enrol a minimum of 150 students during the duration of the projects (minimum 2 programme cycles). This total of 150 students is a collective requirement and the consortium can meet this target by including more higher education institutions as partners. For participating higher education institutions that plan to design and deliver programme(s) at ISCED level 8 (doctoral or equivalent level) in addition to programme(s) at ISCED levels 6 (Bachelor's or equivalent level) and/or 7 (Master's or equivalent level) the minimum number of doctoral students required is not predefined by this call. The awarded projects should aim at training at least 150 additional students (participants) through self-standing modules delivered by consortium members during the duration of the project. High priority will be given to consortia that have high ambitions in terms of the number of students trained and successfully completing the programme(s) and module(s) as well as delivering excellent programmes and modules.

myOVERVIEW
- sign up for personalised information

We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).

Stay informed about what matters to you. By signing up, you can opt in for e-mail notifications and get access to a personalised dashboard that groups all news updates and event announcements in your domain(s).

Only for stakeholders located in Flanders

Latest News

1505 articles available search in articles 

Testimonial

image of Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

Methylomic – Hope & Improved outcomes for Crohn’s disease patients across Europe

The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.